Detalhe da pesquisa
1.
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Liver Int
; 44(1): 139-147, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37787009
2.
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Liver Int
; 43(8): 1663-1676, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183524
3.
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
J Viral Hepat
; 28(2): 410-419, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185325
4.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Liver Int
; 41(2): 295-299, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217778
5.
Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.
Int J Clin Pract
; 75(2): e13593, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32583494
6.
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
J Viral Hepat
; 27(12): 1359-1368, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32707605
7.
C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma.
Oncology
; 96(1): 25-32, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30336489
8.
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Clin Gastroenterol Hepatol
; 13(13): 2342-49.e1-2, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26044319
9.
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Hepatology
; 60(1): 87-97, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24585488
10.
Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B.
Liver Int
; 35(3): 846-53, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24840315
11.
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta.
Liver Int
; 34(8): 1207-15, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24308704
12.
Single-center analysis of the first 304 living-donor liver transplantations in 3 years.
Hepatogastroenterology
; 60(125): 1105-9, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23478145
13.
What does quantitative HBsAg level mean in chronic hepatitis D infection?
Eur J Gastroenterol Hepatol
; 35(3): 320-326, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708303
14.
Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy.
Hepatol Forum
; 3(3): 82-87, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36177099
15.
Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients.
Arch Virol
; 156(12): 2215-20, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21984217
16.
Clinical and Virological Features of Acute Hepatic Exacerbations in Patients With Chronic Hepatitis B Virus Infection.
Cureus
; 13(6): e15937, 2021 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34194888
17.
Brucellosis as a rare cause of granulomatous hepatitis with hepatic and bone marrow granulomas: A case report.
Hepatol Forum
; 2(3): 137-140, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35784902
18.
Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study.
Turk J Gastroenterol
; 32(12): 1019-1028, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34876392
19.
Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
Turk J Gastroenterol
; 31(12): 883-893, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626001
20.
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Lancet Infect Dis
; 19(3): 275-286, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30833068